ClinicalTrials.gov
public full text
Public Domain
Nivolumab Combined With BMS-986253 in HCC Patients
A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC#140986
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer#849852
- Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function#1197939
- Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation#226145
- Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma#807489
Record · ID 1439536
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive